290 related articles for article (PubMed ID: 19761407)
1. Prolyl hydroxylases and therapeutics.
Smith TG; Talbot NP
Antioxid Redox Signal; 2010 Apr; 12(4):431-3. PubMed ID: 19761407
[TBL] [Abstract][Full Text] [Related]
2. HIF-prolyl hydroxylases and cardiovascular diseases.
Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic manipulation of the HIF hydroxylases.
Nagel S; Talbot NP; Mecinović J; Smith TG; Buchan AM; Schofield CJ
Antioxid Redox Signal; 2010 Apr; 12(4):481-501. PubMed ID: 19754349
[TBL] [Abstract][Full Text] [Related]
4. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
5. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection.
Harten SK; Ashcroft M; Maxwell PH
Antioxid Redox Signal; 2010 Apr; 12(4):459-80. PubMed ID: 19737089
[TBL] [Abstract][Full Text] [Related]
6. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors.
Thirstrup K; Christensen S; Møller HA; Ritzén A; Bergström AL; Sager TN; Jensen HS
Pharmacol Res; 2011 Sep; 64(3):268-73. PubMed ID: 21504793
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of a viral prolyl hydroxylase.
Langley GW; Abboud MI; Lohans CT; Schofield CJ
Bioorg Med Chem; 2019 Jun; 27(12):2405-2412. PubMed ID: 30737136
[TBL] [Abstract][Full Text] [Related]
8. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2).
McDonough MA; Li V; Flashman E; Chowdhury R; Mohr C; Liénard BM; Zondlo J; Oldham NJ; Clifton IJ; Lewis J; McNeill LA; Kurzeja RJ; Hewitson KS; Yang E; Jordan S; Syed RS; Schofield CJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9814-9. PubMed ID: 16782814
[TBL] [Abstract][Full Text] [Related]
9. HIF prolyl hydroxylase inhibitors for anemia.
Muchnik E; Kaplan J
Expert Opin Investig Drugs; 2011 May; 20(5):645-56. PubMed ID: 21406036
[TBL] [Abstract][Full Text] [Related]
10. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.
Nangaku M; Izuhara Y; Takizawa S; Yamashita T; Fujii-Kuriyama Y; Ohneda O; Yamamoto M; van Ypersele de Strihou C; Hirayama N; Miyata T
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2548-54. PubMed ID: 17932321
[TBL] [Abstract][Full Text] [Related]
11. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology.
Dao JH; Kurzeja RJ; Morachis JM; Veith H; Lewis J; Yu V; Tegley CM; Tagari P
Anal Biochem; 2009 Jan; 384(2):213-23. PubMed ID: 18952043
[TBL] [Abstract][Full Text] [Related]
12. Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.
Yeoh KK; Chan MC; Thalhammer A; Demetriades M; Chowdhury R; Tian YM; Stolze I; McNeill LA; Lee MK; Woon ECY; Mackeen MM; Kawamura A; Ratcliffe PJ; Mecinović J; Schofield CJ
Org Biomol Chem; 2013 Feb; 11(5):732-745. PubMed ID: 23151668
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?
Karuppagounder SS; Ratan RR
J Cereb Blood Flow Metab; 2012 Jul; 32(7):1347-61. PubMed ID: 22415525
[TBL] [Abstract][Full Text] [Related]
14. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy.
Ratan RR; Siddiq A; Aminova L; Lange PS; Langley B; Ayoub I; Gensert J; Chavez J
Stroke; 2004 Nov; 35(11 Suppl 1):2687-9. PubMed ID: 15472113
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress.
Siddiq A; Aminova LR; Ratan RR
Neurochem Res; 2007; 32(4-5):931-46. PubMed ID: 17342411
[TBL] [Abstract][Full Text] [Related]
16. Non-hypoxic activation of the negative regulatory feedback loop of prolyl-hydroxylase oxygen sensors.
Tug S; Delos Reyes B; Fandrey J; Berchner-Pfannschmidt U
Biochem Biophys Res Commun; 2009 Jul; 384(4):519-23. PubMed ID: 19427832
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.
Rabinowitz MH
J Med Chem; 2013 Dec; 56(23):9369-402. PubMed ID: 23977883
[TBL] [Abstract][Full Text] [Related]
18. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells.
Johansen JL; Sager TN; Lotharius J; Witten L; Mørk A; Egebjerg J; Thirstrup K
J Neurochem; 2010 Oct; 115(1):209-19. PubMed ID: 20649842
[TBL] [Abstract][Full Text] [Related]
19. The role of HIF prolyl hydroxylases in tumour growth.
Jokilehto T; Jaakkola PM
J Cell Mol Med; 2010 Apr; 14(4):758-70. PubMed ID: 20178464
[TBL] [Abstract][Full Text] [Related]
20. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection.
Siddiq A; Aminova LR; Ratan RR
Front Biosci; 2008 Jan; 13():2875-87. PubMed ID: 17981760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
